Larimar Therapeutics, Inc. (LRMR) stock

LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 6/30

$2.70−0.03 (-1.10%)

Close on Nov 12, 2026Market cap $280.48MP/E –Yield –

Larimar Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Larimar Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?